Patents by Inventor Young-Chan Chae
Young-Chan Chae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11967862Abstract: In a driving system, first and second inverters are connected to a driving motor, one end of a stator winding through which 3-phase current flows is connected to an output line of the first inverter, and the other end of the stator winding is connected to an output line of the second inverter. A winding pattern of the driving motor includes: coils wound in slots defined in the stator and to which 3-phase current is applied; coils wound on innermost and outermost sides based on a direction toward a rotating shaft of the driving motor in the slots, and being energized by different AC phases; and coils disposed between a first coil located on the outermost side and a second coil located on the innermost side, and being energized by the same AC phases as those of the first and second coils.Type: GrantFiled: November 16, 2021Date of Patent: April 23, 2024Assignees: HYUNDAI MOTOR COMPANY, KIA CORPORATIONInventors: Woong Chan Chae, Jung Shik Kim, Jong Hoon Lee, Byung Kwan Son, Sang Hoon Moon, Young Jin Shin
-
Publication number: 20220348620Abstract: The present invention relates to Mitochondrial Fission Factor (MFF)-derived peptides or peptide mimetics and to methods of making MFF-derived peptides or peptide mimetics. Also provided are methods of treating a disease in a subject in need thereof, comprising administering to the subject an effective amount of a MFF-derived peptide or peptide mimetic.Type: ApplicationFiled: September 9, 2020Publication date: November 3, 2022Inventors: Dario Altieri, Young Chan Chae, Jae Ho Seo
-
Publication number: 20210069218Abstract: Methods of stimulating anti-tumor activity in a subject with cancer are provided. The methods include administering to a subject in need thereof a low dose low dosage of a composition comprising a molecule that inhibits Hsp90 linked to a mitochondria-penetrating moiety; and administering to the subject an effective amount of an inhibitor of autophagy or glycolysis.Type: ApplicationFiled: March 27, 2020Publication date: March 11, 2021Inventors: Young Chan Chae, Dario C. Altieri
-
Patent number: 9650638Abstract: This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and/or cancer metastasis and/or a composition for diagnosis of cancer and/or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer/cancer metastasis more effectively.Type: GrantFiled: November 12, 2012Date of Patent: May 16, 2017Assignees: UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY), POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Pann-Ghill Suh, Ii Shin Kim, Yu Jin Lee, Youn Dong Kim, Young Chan Chae, Jong Hun Im, Sung Ho Ryu
-
Patent number: 9309515Abstract: Disclosed are a DNA aptamer specifically binding to the Her2 (ERBB2) receptor involved in the onset of breast cancer, a composition for the suppression of cancer metastasis comprising the same as an active ingredient, and a composition for the diagnosis of cancer comprising the same as an active ingredient. Due to its binding mechanism being different from that of the conventional antibody, the aptamer can be effectively used for suppressing cancer metastasis and diagnosing cancer.Type: GrantFiled: August 10, 2011Date of Patent: April 12, 2016Assignees: POSTECH ACADEMY-INDUSTRY FOUNDATION, KOREA FOOD & DRUG ADMINISTRATIONInventors: Jung Hwan Lee, Young Chan Chae, Youngdong Kim, Hyungu Kang, Jong Hun Im, Jong In Kim, Ki Seok Kim, Sung Key Jang, Il Ung Oh, Min Jeong Choi, Won Jun Kang
-
Publication number: 20160015725Abstract: Methods of stimulating anti-tumor activity in a subject with cancer are provided. The methods include administering to a subject in need thereof a low dose low dosage of a composition comprising a molecule that inhibits Hsp90 linked to a mitochondria-penetrating moiety; and administering to the subject an effective amount of an inhibitor of autophagy or glycolysis.Type: ApplicationFiled: February 14, 2013Publication date: January 21, 2016Inventors: Young Chan Chae, Dario C. Altieri
-
Publication number: 20150359911Abstract: The present invention relates to DNA aptamer specifically binding to integrin ?v?3, and a composition for diagnosis of cancer or cancer metastasis comprising the same as an active ingredient. And, the present invention relates to a composition for imaging tumor regions comprising the aptamer, and a contrast medium comprising the same.Type: ApplicationFiled: July 31, 2013Publication date: December 17, 2015Inventors: Jung Hwan LEE, Seungjoo HAAM, Yong-min HUH, Young Chan CHAE, Sung Ho RYU, Eun-kyung LIM, Jong In KIM
-
Publication number: 20150337309Abstract: This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and/or cancer metastasis and/or a composition for diagnosis of cancer and/or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer/cancer metastasis more effectively.Type: ApplicationFiled: November 12, 2012Publication date: November 26, 2015Inventors: Pann-Ghill SUH, Il Shin KIM, Yu Jin LEE, Youn Dong KIM, Young Chan CHAE, Jong Hun IM, Sung Ho RYU
-
Patent number: 9018186Abstract: Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.Type: GrantFiled: September 24, 2013Date of Patent: April 28, 2015Assignee: Postech Academy-Industry FoundationInventors: Jung Hwan Lee, Soon Hag Kim, Mi-Jin Kwon, Hyungu Kang, Sung Ho Ryu, Jong In Kim, Youndong Kim, Young Chan Chae, Sung Key Jang, Jong Hun Im, Sun Hak Lee, Hye Jung Lee, Eun Jung Jang, Ki Seok Kim
-
Patent number: 9018185Abstract: Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.Type: GrantFiled: September 24, 2013Date of Patent: April 28, 2015Assignee: Postech Academy-Industry FoundationInventors: Jung Hwan Lee, Soon Hag Kim, Mi-Jin Kwon, Hyungu Kang, Sung Ho Ryu, Jong In Kim, Youndong Kim, Young Chan Chae, Sung Key Jang, Jong Hun Im, Sun Hak Lee, Hye Jung Lee, Eun Jung Jang, Ki Seok Kim
-
Publication number: 20150005368Abstract: Disclosed are a DNA aptamer specifically binding to the Her2 (ERBB2) receptor involved in the onset of breast cancer, a composition for the suppression of cancer metastasis comprising the same as an active ingredient, and a composition for the diagnosis of cancer comprising the same as an active ingredient. Due to its binding mechanism being different from that of the conventional antibody, the aptamer can be effectively used for suppressing cancer metastasis and diagnosing cancer.Type: ApplicationFiled: August 10, 2011Publication date: January 1, 2015Applicants: KOREA FOOD & DRUG ADMINISTRATION, POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Jung Hwan Lee, Young Chan Chae, Youndong Kim, Hyungu Kang, Jong Hun Im, Jong In Kim, Ki Seok Kim, Sung Key Jang, II Ung Oh, Min Jeong Choi, Won Jun Kang
-
Publication number: 20140271667Abstract: A method for inhibiting tumor cell migration or metastasis of a cancer in a mammalian subject comprises one or more of the steps of administering to a subject a therapeutically effective amount of a composition comprising a molecule that: suppresses focal adhesion kinase (FAK) activity or phosphorylation; suppresses ULK1 kinase activity; suppresses activation or signaling of the mTORC1 (Ser757) pathway; activates AMPK; activates FIP200; or activates LKB1, in a cancer cell. Still another method of inhibiting tumor cell migration involves inhibiting phosphorylation of ULK1 on Ser757 in subjects with lung cancer. Suppressing activation or signaling of the mTORC1 (Ser757) pathway in subjects is in one aspect useful in treating lung cancer.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: The Wistar Institute of Anatomy and BiologyInventors: Dario C. Altieri, Young Chan Chae
-
Publication number: 20140213636Abstract: Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.Type: ApplicationFiled: September 24, 2013Publication date: July 31, 2014Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: JUNG HWAN LEE, SOON HAG KIM, MI-JIN KWON, HYUNGU KANG, SUNG HO RYU, JONG IN KIM, YOUNDONG KIM, YOUNG CHAN CHAE, SUNG KEY JANG, JONG HUN IM, SUN HAK LEE, HYE JUNG LEE, EUN JUNG JANG, KI SEOK KIM
-
Patent number: 8785132Abstract: The present invention provides methods for identifying the plurality of aptamers that bind to different sites of a target molecule and methods for using the same, for example, in sandwich assays. In particular, the plurality of aptamers binding to different sites of the target molecules is identified from a library of aptamers identified from the same SELEX process.Type: GrantFiled: April 22, 2011Date of Patent: July 22, 2014Assignee: Postech Academy-Industry FoundationInventors: Young-Chan Chae, Youn-Dong Kim, Jung-Hwan Lee, Ki-Seok Kim, Dong-II Han, Bum-Su Park, Seung-Jin Lee, Jong-Hun Im, Jong-In Kim, Sung-Ho Ryu, Sung-Key Jang
-
Publication number: 20140093886Abstract: Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.Type: ApplicationFiled: September 24, 2013Publication date: April 3, 2014Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: JUNG HWAN LEE, SOON HAG KIM, MI-JIN KWON, HYUNGU KANG, SUNG HO RYU, JONG IN KIM, YOUNDONG KIM, YOUNG CHAN CHAE, SUNG KEY JANG, JONG HUN IM, SUN HAK LEE, HYE JUNG LEE, EUN JUNG JANG, KI SEOK KIM
-
Patent number: 8569252Abstract: Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.Type: GrantFiled: April 14, 2010Date of Patent: October 29, 2013Assignees: Postech Academy-Industry Foundation, PoscoInventors: Jung-Hwan Lee, Soon-Hag Kim, Mi-Jin Kwon, Hyun-Gu Kang, Sung-Ho Ryu, Jong-In Kim, Youn-Dong Kim, Young-Chan Chae, Sung-Key Jang, Jong-Hun Im, Sun-Hak Lee, Hye-Jung Lee, Eun-Jung Jang, Ki-Seok Kim
-
Publication number: 20110262922Abstract: The present invention provides methods for identifying the plurality of aptamers that bind to different sites of a target molecule and methods for using the same, for example, in sandwich assays. In particular, the plurality of aptamers binding to different sites of the target molecules is identified from a library of aptamers identified from the same SELEX process.Type: ApplicationFiled: April 22, 2011Publication date: October 27, 2011Applicants: POSCO, POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Young-Chan CHAE, Youn-Dong Kim, Jung-Hwan Lee, Ki-Seok Kim, Dong-II Han, Bum-Su Park, Seung-Jin Lee, Jong-Hun Im, Jong-In Kim, Sung-Ho Ryu, Sung-Key Jang
-
Publication number: 20100317723Abstract: Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.Type: ApplicationFiled: April 14, 2010Publication date: December 16, 2010Applicants: POSTECH ACADEMY-INDUSTRY FOUDATION, POSCOInventors: JUNG-HWAN LEE, SOON-HAG KIM, MI-JIN KWON, HYUN-GU KANG, SUNG-HO RYU, JONG-IN KIM, YOUN-DONG KIM, YOUNG-CHAN CHAE, SUNG-KEY JANG, JONG-HUN IM, SUN-HAK LEE, HYE-JUNG LEE, EUN-JUNG JANG, KI-SEOK KIM
-
Publication number: 20090312250Abstract: The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes.Type: ApplicationFiled: July 16, 2007Publication date: December 17, 2009Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Sung-Ho Ryu, Hye-Young Lee, Kyung-Moo Yea, Byoung-Dae Lee, Young-Chan Chae, Hyeon-Soo Kim, Seon-Hee Kim, Pann-Ghill Suh